# STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
Canonical URL: https://biopharmsignal.com/news/MARKET/stat-merck-strikes-voluntary-licensing-deals-in-poor-countries-for-an-experiment-ac73ba8a
Ticker: MARKET
Company: MARKET
Source: STAT News
Published: 2026-07-24 10:45 EST
Original Source URL: https://www.statnews.com/pharmalot/2026/07/24/merck-experimental-hiv-prevention-pill-licensing-deals/?utm_campaign=rss
## Summary

Merck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production started quickly.

## Article Body
By Ed Silverman

July 24, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter .

Amid rising concern over efforts to contain HIV, Merck has reached voluntary licensing deals with seven companies to make generic versions of an experimental, once-a-month prevention pill in 129 low- and middle-income countries.

The agreements will allow the manufacturers — three of which are based in Africa and four in India — to sell generic versions to both public and private buyers, which is designed to ensure the medicine becomes available to the widest possible population. Moreover, the deals are royalty free, which makes it easier for the generic companies to predict costs.

The timing of the announcement is notable because Merck is striking these deals while its medicine, known as alimatravir, is currently undergoing a pair of late-stage clinical trials. By doing so now, the company believes it will help the generic makers plan for wide-scale production and the necessary steps to receive regulatory approvals around the world.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe
## Recent Company News
- 2026-07-24 11:59 EST — [A new, separate outbreak of the diarrhea-causing parasite](https://biopharmsignal.com/news/MARKET/a-new-separate-outbreak-of-the-diarrhea-causing-parasite-f394209e) — Source: STAT News
- 2026-07-24 10:45 EST — [STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill](https://biopharmsignal.com/news/MARKET/stat-merck-strikes-voluntary-licensing-deals-in-poor-countries-for-an-experiment-ac73ba8a) — Source: STAT News
- 2026-07-24 08:30 EST — [Opinion: I may be one of the last middle-class medical students who could afford to become a doctor](https://biopharmsignal.com/news/MARKET/opinion-i-may-be-one-of-the-last-middle-class-medical-students-who-could-afford--aa8ed1af) — Source: STAT News
- 2026-07-24 08:30 EST — [Opinion: The U.S. pharmaceutical supply chain problem is not about China](https://biopharmsignal.com/news/MARKET/opinion-the-u-s-pharmaceutical-supply-chain-problem-is-not-about-china-bc23af27) — Source: STAT News
- 2026-07-24 08:30 EST — [Senate advances MAHA-friendly bill for food warning labels and junk food ad bans](https://biopharmsignal.com/news/MARKET/senate-advances-maha-friendly-bill-for-food-warning-labels-and-junk-food-ad-bans-80999984) — Source: STAT News
## Related News
- 2026-07-24 12:00 EST — NAMS — [NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-and-menarini-group-receive-positive-chmp-opinion-recommendin-6e39bfc3)
- 2026-07-24 11:59 EST — MARKET — [A new, separate outbreak of the diarrhea-causing parasite](https://biopharmsignal.com/news/MARKET/a-new-separate-outbreak-of-the-diarrhea-causing-parasite-f394209e)
- 2026-07-24 08:30 EST — MARKET — [Opinion: I may be one of the last middle-class medical students who could afford to become a doctor](https://biopharmsignal.com/news/MARKET/opinion-i-may-be-one-of-the-last-middle-class-medical-students-who-could-afford--aa8ed1af)
- 2026-07-24 08:30 EST — MARKET — [Opinion: The U.S. pharmaceutical supply chain problem is not about China](https://biopharmsignal.com/news/MARKET/opinion-the-u-s-pharmaceutical-supply-chain-problem-is-not-about-china-bc23af27)
- 2026-07-24 08:30 EST — MARKET — [Senate advances MAHA-friendly bill for food warning labels and junk food ad bans](https://biopharmsignal.com/news/MARKET/senate-advances-maha-friendly-bill-for-food-warning-labels-and-junk-food-ad-bans-80999984)